Collaborative Care for Polysubstance Use in Primary Care Settings (Co-Care)

Description

The purpose of this trial is to test the efficacy of a collaborative care intervention to address opioid- and/or stimulant-involved polysubstance use in adult primary care patients with moderate to severe substance use disorders (SUD). The primary aims are to reduce days of opioid use (illicit or nonmedical opioid use), days of illicit stimulant use (cocaine, methamphetamine), and days of heavy alcohol use.

Conditions

Substance Use

Talk to us

Study Overview

On this page

Study Details

Study overview

The purpose of this trial is to test the efficacy of a collaborative care intervention to address opioid- and/or stimulant-involved polysubstance use in adult primary care patients with moderate to severe substance use disorders (SUD). The primary aims are to reduce days of opioid use (illicit or nonmedical opioid use), days of illicit stimulant use (cocaine, methamphetamine), and days of heavy alcohol use.

NIDA CTN Protocol 0139: Collaborative Care for Polysubstance Use in Primary Care Settings (Co-Care)

Collaborative Care for Polysubstance Use in Primary Care Settings (Co-Care)

Condition
Substance Use
Intervention / Treatment

-

Contacts and Locations

Torrance

Harbor-UCLA Medical Center, Torrance, California, United States, 90502

New York

NYU Langone Health, New York, New York, United States, 10016

New York

The Institute for Family Health, New York, New York, United States, 10025

Enterprise

Winding Waters Medical Clinic, Enterprise, Oregon, United States, 97828

Lancaster

Union Community Care, Lancaster, Pennsylvania, United States, 17603

Houston

Harris Health, Houston, Texas, United States, 77030

Bellingham

Sea Mar Community Health Centers, Bellingham, Washington, United States, 98226

Madison

Wisconsin Research & Education Network, Madison, Wisconsin, United States, 53705

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Licensed medical professional (MD, DO, NP, PA) who is able to prescribe controlled substances (Schedule III), or medical trainee meeting the requirements below.
  • * Serves as a primary care provider to adult patients (18 years of age and over) of the study clinic(s) during direct patient care sessions.
  • * Willing to be randomized to either of the study conditions. a. Medical trainees (physicians who are residents or fellows), are eligible if they have at least one continuity clinic session per week on average in the study clinic. Trainees must have plans to be working in a study clinic for approximately 8 months or longer. They must be able to provide prescriptions for controlled substances (Schedule III) either directly or through their preceptor(s).
  • * Definite plan to resign from the clinic in the next eight months, per PCP self-report. Residents and fellows will need at least eight months before training completion to enroll.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

NYU Langone Health,

Jennifer McNeely, MD, PRINCIPAL_INVESTIGATOR, NYU Langone Health

Study Record Dates

2026-12